Yihan Sun1,2, Jae Hyun Kim1,2, Kiran Vangipuram1, Daniel F Hayes3, Ellen M L Smith4, Larisa Yeomans1,2, N Lynn Henry5, Kathleen A Stringer1,2, Daniel L Hertz6,7. 1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA. 2. The NMR Metabolomics Laboratory, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. 3. Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA. 4. Department of Health Behavior and Biological Sciences, University of Michigan School of Nursing, Ann Arbor, MI, USA. 5. Huntsman Cancer Institute, University of Utah Health Care, Salt Lake City, UT, USA. 6. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA. DLHertz@med.umich.edu. 7. Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA. DLHertz@med.umich.edu.
Abstract
PURPOSE: Approximately 25% of breast cancer patients experience treatment delays or discontinuation due to paclitaxel-induced peripheral neuropathy (PN). Currently, there are no predictive biomarkers of PN. Pharmacometabolomics is an informative tool for biomarker discovery of drug toxicity. We conducted a secondary whole blood pharmacometabolomics analysis to assess the association between pretreatment metabolome, early treatment-induced metabolic changes, and the development of PN. METHODS: Whole blood samples were collected pre-treatment (BL), just before the end of the first paclitaxel infusion (EOI), and 24 h after the first infusion (24H) from sixty patients with breast cancer receiving (80 mg/m2) weekly treatment. Neuropathy was assessed at BL and prior to each infusion using the sensory subscale (CIPN8) of the EORTC CIPN20 questionnaire. Blood metabolites were quantified from 1-D-1H-nuclear magnetic resonance spectra using Chenomx® software. Metabolite concentrations were normalized in preparation for Pearson correlation and one-way repeated measures ANOVA with multiple comparisons corrected by false discovery rate (FDR). RESULTS: Pretreatment histidine, phenylalanine, and threonine concentrations were inversely associated with maximum change in CIPN8 (ΔCIPN8) (p < 0.02; FDR ≤ 25%). Paclitaxel caused a significant change in concentrations of 2-hydroxybutyrate, 3-hydroxybutyrate, pyruvate, o-acetylcarnitine, and several amino acids from BL to EOI and/or 24H (p < 0.05; FDR ≤ 25%), although these changes were not associated with ΔCIPN8. CONCLUSIONS: Whole blood metabolomics is a feasible approach to identify potential biomarker candidates of paclitaxel-induced PN. The findings suggest that pretreatment concentrations of histidine, phenylalanine, and threonine may be predictive of the severity of future PN and paclitaxel-induced metabolic changes may be related to disruption of energy homeostasis.
PURPOSE: Approximately 25% of breast cancerpatients experience treatment delays or discontinuation due to paclitaxel-induced peripheral neuropathy (PN). Currently, there are no predictive biomarkers of PN. Pharmacometabolomics is an informative tool for biomarker discovery of drug toxicity. We conducted a secondary whole blood pharmacometabolomics analysis to assess the association between pretreatment metabolome, early treatment-induced metabolic changes, and the development of PN. METHODS: Whole blood samples were collected pre-treatment (BL), just before the end of the first paclitaxel infusion (EOI), and 24 h after the first infusion (24H) from sixty patients with breast cancer receiving (80 mg/m2) weekly treatment. Neuropathy was assessed at BL and prior to each infusion using the sensory subscale (CIPN8) of the EORTC CIPN20 questionnaire. Blood metabolites were quantified from 1-D-1H-nuclear magnetic resonance spectra using Chenomx® software. Metabolite concentrations were normalized in preparation for Pearson correlation and one-way repeated measures ANOVA with multiple comparisons corrected by false discovery rate (FDR). RESULTS: Pretreatment histidine, phenylalanine, and threonine concentrations were inversely associated with maximum change in CIPN8 (ΔCIPN8) (p < 0.02; FDR ≤ 25%). Paclitaxel caused a significant change in concentrations of 2-hydroxybutyrate, 3-hydroxybutyrate, pyruvate, o-acetylcarnitine, and several amino acids from BL to EOI and/or 24H (p < 0.05; FDR ≤ 25%), although these changes were not associated with ΔCIPN8. CONCLUSIONS: Whole blood metabolomics is a feasible approach to identify potential biomarker candidates of paclitaxel-induced PN. The findings suggest that pretreatment concentrations of histidine, phenylalanine, and threonine may be predictive of the severity of future PN and paclitaxel-induced metabolic changes may be related to disruption of energy homeostasis.
Entities:
Keywords:
Breast cancer; Chemotherapy-induced peripheral neuropathy; Metabolomics; Nuclear magnetic resonance; Paclitaxel
Authors: Barbara K Bennett; Susanna B Park; Cindy S-Y Lin; Michael L Friedlander; Matthew C Kiernan; David Goldstein Journal: Support Care Cancer Date: 2012-03-17 Impact factor: 3.603
Authors: Hyuk Nam Kwon; Mina Kim; He Wen; Sunmi Kang; Hye-Ji Yang; Myung-Joo Choi; Hee Seung Lee; DalWoong Choi; In Suh Park; Young Ju Suh; Soon-Sun Hong; Sunghyouk Park Journal: Kidney Int Date: 2010-10-27 Impact factor: 10.612
Authors: Wenyun Lu; Xiaoyang Su; Matthias S Klein; Ian A Lewis; Oliver Fiehn; Joshua D Rabinowitz Journal: Annu Rev Biochem Date: 2017-06-20 Impact factor: 23.643
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: R Michael Baldwin; Kouros Owzar; Hitoshi Zembutsu; Aparna Chhibber; Michiaki Kubo; Chen Jiang; Dorothy Watson; Rachel J Eclov; Joel Mefford; Howard L McLeod; Paula N Friedman; Clifford A Hudis; Eric P Winer; Eric M Jorgenson; John S Witte; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz Journal: Clin Cancer Res Date: 2012-07-27 Impact factor: 12.531
Authors: Ciao-Sin Chen; Ellen M Lavoie Smith; Kathleen A Stringer; N Lynn Henry; Daniel L Hertz Journal: Breast Cancer Res Treat Date: 2022-06-28 Impact factor: 4.624
Authors: Li Chen; Ciao-Sin Chen; Yihan Sun; N Lynn Henry; Kathleen A Stringer; Daniel L Hertz Journal: Cancer Chemother Pharmacol Date: 2021-06-05 Impact factor: 3.288
Authors: Anukriti Sharma; Ken B Johnson; Bihua Bie; Emily E Rhoades; Alper Sen; Yuri Kida; Jennifer Hockings; Alycia Gatta; Jacqueline Davenport; Connie Arcangelini; Jennifer Ritzu; Jennifer DeVecchio; Ron Hughen; Mei Wei; G Thomas Budd; N Lynn Henry; Charis Eng; Joseph Foss; Daniel M Rotroff Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec
Authors: Ahmet Yardım; Fatih Mehmet Kandemir; Selim Çomaklı; Selçuk Özdemir; Cuneyt Caglayan; Sefa Kucukler; Hamit Çelik Journal: Neurochem Res Date: 2020-11-17 Impact factor: 3.996